United Laboratories International Holdings Future Growth
Future criteria checks 1/6
United Laboratories International Holdings is forecast to grow earnings and revenue by 5% and 6.8% per annum respectively. EPS is expected to grow by 4.8% per annum. Return on equity is forecast to be 19.5% in 3 years.
Key information
5.0%
Earnings growth rate
4.8%
EPS growth rate
Pharmaceuticals earnings growth | 11.1% |
Revenue growth rate | 6.8% |
Future return on equity | 19.5% |
Analyst coverage | Good |
Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Nov 11The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Oct 23Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching
Aug 30Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified
Feb 29The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement
Jan 04United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt
Dec 14With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case
Nov 26Is United Laboratories International Holdings (HKG:3933) A Risky Investment?
Aug 31Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?
Aug 10United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet
Dec 23Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?
Oct 19Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
Aug 30Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?
Mar 08The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It
Feb 18The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 03Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?
Jan 19We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide
Jan 04These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Dec 20What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?
Dec 07The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?
Nov 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 16,763 | 3,295 | N/A | 3,756 | 7 |
12/31/2025 | 15,781 | 3,119 | N/A | 3,545 | 8 |
12/31/2024 | 14,936 | 2,975 | N/A | 3,545 | 8 |
6/30/2024 | 14,009 | 2,908 | 1,420 | 3,088 | N/A |
3/31/2024 | 13,875 | 2,805 | 1,267 | 2,763 | N/A |
12/31/2023 | 13,740 | 2,701 | 1,114 | 2,439 | N/A |
9/30/2023 | 13,399 | 2,469 | 1,376 | 2,504 | N/A |
6/30/2023 | 13,059 | 2,236 | 1,637 | 2,568 | N/A |
3/31/2023 | 12,197 | 1,909 | 1,444 | 2,300 | N/A |
12/31/2022 | 11,334 | 1,581 | 1,251 | 2,031 | N/A |
9/30/2022 | 10,750 | 1,288 | 1,066 | 1,683 | N/A |
6/30/2022 | 10,166 | 995 | 882 | 1,336 | N/A |
3/31/2022 | 9,935 | 991 | 968 | 1,439 | N/A |
12/31/2021 | 9,703 | 988 | 1,055 | 1,543 | N/A |
9/30/2021 | 9,445 | 1,056 | 1,047 | 1,647 | N/A |
6/30/2021 | 9,187 | 1,123 | 1,039 | 1,752 | N/A |
3/31/2021 | 8,980 | 913 | 1,035 | 1,660 | N/A |
12/31/2020 | 8,772 | 703 | 1,030 | 1,568 | N/A |
9/30/2020 | 8,690 | 626 | 1,128 | 1,625 | N/A |
6/30/2020 | 8,607 | 549 | 1,226 | 1,683 | N/A |
3/31/2020 | 8,500 | 595 | 1,293 | 1,742 | N/A |
12/31/2019 | 8,393 | 642 | 1,361 | 1,801 | N/A |
9/30/2019 | 8,100 | 765 | 1,147 | 1,618 | N/A |
6/30/2019 | 7,808 | 888 | 932 | 1,436 | N/A |
3/31/2019 | 7,659 | 785 | 806 | 1,324 | N/A |
12/31/2018 | 7,511 | 683 | 681 | 1,213 | N/A |
9/30/2018 | 7,395 | 373 | 640 | 1,104 | N/A |
6/30/2018 | 7,280 | 64 | 599 | 995 | N/A |
3/31/2018 | 7,053 | 73 | N/A | 883 | N/A |
12/31/2017 | 6,827 | 82 | N/A | 770 | N/A |
9/30/2017 | 6,640 | -34 | N/A | 957 | N/A |
6/30/2017 | 6,454 | -150 | N/A | 1,144 | N/A |
3/31/2017 | 6,266 | -211 | N/A | 1,109 | N/A |
12/31/2016 | 6,078 | -272 | N/A | 1,074 | N/A |
9/30/2016 | 6,083 | -216 | N/A | 976 | N/A |
6/30/2016 | 6,076 | -159 | N/A | 875 | N/A |
3/31/2016 | 6,195 | -32 | N/A | 1,182 | N/A |
12/31/2015 | 6,446 | 92 | N/A | 1,516 | N/A |
9/30/2015 | 6,597 | 148 | N/A | 1,522 | N/A |
6/30/2015 | 6,711 | 201 | N/A | 1,521 | N/A |
3/31/2015 | 6,565 | 373 | N/A | 1,460 | N/A |
12/31/2014 | 6,422 | 545 | N/A | 1,400 | N/A |
9/30/2014 | 6,179 | 552 | N/A | 1,436 | N/A |
6/30/2014 | 6,101 | 574 | N/A | 1,511 | N/A |
3/31/2014 | 6,112 | 306 | N/A | 1,347 | N/A |
12/31/2013 | 5,972 | 38 | N/A | 1,155 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3933's forecast earnings growth (5% per year) is above the savings rate (2.3%).
Earnings vs Market: 3933's earnings (5% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).
High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3933's revenue (6.8% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).
High Growth Revenue: 3933's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (19.5%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/30 10:15 |
End of Day Share Price | 2024/12/30 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The United Laboratories International Holdings Limited is covered by 31 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ying Shao | BofA Global Research |
Yue-Kwong Lui | CGS International |
Bo Yu | China International Capital Corporation Limited |